Fate Therapeutics Inc (FATE) concluded trading on Thursday at a closing price of $5.04, with 2.33 million shares of worth about $11.74 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 149.50% during that period and on April 18, 2024 the price saw a loss of about -4.36%. Currently the company’s common shares owned by public are about 98.63M shares, out of which, 86.74M shares are available for trading.
Stock saw a price change of -15.29% in past 5 days and over the past one month there was a price change of -28.00%. Year-to-date (YTD), FATE shares are showing a performance of 34.76% which decreased to -19.10% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.63 but also hit the highest price of $8.83 during that period. The average intraday trading volume for Fate Therapeutics Inc shares is 2.82 million. The stock is currently trading -23.87% below its 20-day simple moving average (SMA20), while that difference is down -26.96% for SMA50 and it goes to 23.30% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fate Therapeutics Inc (NASDAQ: FATE) currently have 98.63M outstanding shares and institutions hold larger chunk of about 103.91% of that.
The stock has a current market capitalization of $500.17M and its 3Y-monthly beta is at 1.74. It has posted earnings per share of -$1.63 in the same period. It has Quick Ratio of 8.48 while making debt-to-equity ratio of 0.28. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FATE, volatility over the week remained 7.74% while standing at 7.56% over the month.
Analysts are in expectations that Fate Therapeutics Inc (FATE) stock would likely to be making an EPS of $FAT Brands Inc. in the current quarter, while forecast for next quarter EPS is $7.05 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $RATE which is $FITE at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $INNOVATE Corp. in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -17.51% while it is estimated to increase by 9.20% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on March 27, 2023 offering an Equal weight rating for the stock and assigned a target price of $6 to it. Coverage by H.C. Wainwright stated Fate Therapeutics Inc (FATE) stock as a Neutral in their note to investors on January 24, 2023, suggesting a price target of $7 for the stock. On January 06, 2023, Wedbush Downgrade their recommendations, while on January 06, 2023, Truist Downgrade their ratings for the stock with a price target of $7. Stock get a Hold rating from Stifel on January 06, 2023.
